EP0859779A4 - Enzyme de conversion d'interleukine et apoptose - Google Patents

Enzyme de conversion d'interleukine et apoptose

Info

Publication number
EP0859779A4
EP0859779A4 EP96932941A EP96932941A EP0859779A4 EP 0859779 A4 EP0859779 A4 EP 0859779A4 EP 96932941 A EP96932941 A EP 96932941A EP 96932941 A EP96932941 A EP 96932941A EP 0859779 A4 EP0859779 A4 EP 0859779A4
Authority
EP
European Patent Office
Prior art keywords
apoptosis
converting enzyme
interleukin converting
interleukin
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96932941A
Other languages
German (de)
English (en)
Other versions
EP0859779A1 (fr
Inventor
Mark Alan Levy
Dennis Lee
John Gerald Gleason
Andrew William Taylor
David Francis Corbertt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Ltd
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd, SmithKline Beecham Corp filed Critical SmithKline Beecham Ltd
Publication of EP0859779A1 publication Critical patent/EP0859779A1/fr
Publication of EP0859779A4 publication Critical patent/EP0859779A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
EP96932941A 1995-08-31 1996-08-29 Enzyme de conversion d'interleukine et apoptose Withdrawn EP0859779A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US308295P 1995-08-31 1995-08-31
US3082P 1995-08-31
PCT/US1996/013967 WO1997008174A1 (fr) 1995-08-31 1996-08-29 Enzyme de conversion d'interleukine et apoptose

Publications (2)

Publication Number Publication Date
EP0859779A1 EP0859779A1 (fr) 1998-08-26
EP0859779A4 true EP0859779A4 (fr) 2000-04-12

Family

ID=21704039

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96932941A Withdrawn EP0859779A4 (fr) 1995-08-31 1996-08-29 Enzyme de conversion d'interleukine et apoptose

Country Status (3)

Country Link
EP (1) EP0859779A4 (fr)
JP (1) JPH11511463A (fr)
WO (1) WO1997008174A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016227A1 (fr) 1996-10-15 1998-04-23 G.D. Searle & Co. Application d'inhibiteurs de la cyclogenase-2 au traitement et a la prevention du processus neoplasique
US6270980B1 (en) 1997-06-05 2001-08-07 Idun Pharmaceuticals, Inc. Rapid methods for identifying modifiers of cellular apoptosis activity
WO1999046248A1 (fr) 1998-03-09 1999-09-16 Vertex Pharmaceuticals Incorporated DERIVES DE LA 1,2-DIAZEPANE INHIBITEURS DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE-1$g(b)
CA2324226C (fr) 1998-03-19 2012-06-05 Vertex Pharmaceuticals Incorporated Inhibiteurs de caspases
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
JP2002322068A (ja) * 2001-02-26 2002-11-08 Japan Science & Technology Corp 血管再生促進剤
CA2451955C (fr) 2001-06-26 2015-09-29 Abgenix, Inc. Anticorps opgl
CN104178491B (zh) 2002-09-06 2018-07-03 安姆根有限公司 治疗性人抗-il-1r1单克隆抗体
AU2005249503B2 (en) 2003-11-10 2011-08-25 Vertex Pharmaceuticals Incorporated ICE inhibitors for the treatment of autoinflammatory diseases
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
WO2020035482A1 (fr) 2018-08-13 2020-02-20 Iltoo Pharma Combinaison d'interleukine 2 et d'un inhibiteur de l'interleukine 1, conjugués et utilisations thérapeutiques de celle-ci
EP4526469A1 (fr) 2022-05-16 2025-03-26 Institut National de la Santé et de la Recherche Médicale Procédés d'évaluation de l'épuisement de cellules souches hématopoïétiques induites par une inflammation chronique
WO2026082873A1 (fr) 2024-10-17 2026-04-23 Institut National de la Santé et de la Recherche Médicale Utilisation d'inhibiteurs de caspase-1 pour le traitement de l'érythropoïèse inefficace chez des patients souffrant de drépanocytose

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124081A2 (fr) * 1983-05-02 1984-11-07 Merck & Co. Inc. Céphalosporinesulfones comme agents anti-inflammatoires et anti-dégénératifs, compositions pharmaceutiques les contenant et procédés pour les fabriquer
EP0267723A2 (fr) * 1986-11-12 1988-05-18 Merck & Co. Inc. Sulfones de céphalosporine substituées comme agents anti-inflammatoires et anti-dégénératifs
WO1989010926A1 (fr) * 1988-05-13 1989-11-16 Farmitalia Carlo Erba S.R.L. Derives d'acides 1,1-dioxo-cephem-4-carbothioliques
EP0411929A1 (fr) * 1989-08-01 1991-02-06 Merck & Co. Inc. Procédé pour la préparation de céphèmes 1,1-dioxo-7-substituées
WO1991004977A1 (fr) * 1989-10-06 1991-04-18 Synphar Laboratories, Inc. Nouveaux derives de sulfone de cephalosporine 2-spirocyclopropyle et procedes de preparation de tels derives
GB2266526A (en) * 1992-03-17 1993-11-03 Merck & Co Inc Substituted cephalosporin sulfones useful in the treatment of leukemia
GB2266525A (en) * 1992-03-17 1993-11-03 Merck & Co Inc Substituted cephalosporin sulfone compositions useful in the treatment of leukemia
DE4341332A1 (de) * 1992-12-04 1994-06-09 Erba Carlo Spa 4-Alkyl- und 4-Alkenyl-Delta-3-Cephemsulfone
WO1994028003A1 (fr) * 1993-05-20 1994-12-08 Pharmacia S.P.A. Cefemsulfones tricycliques
WO1995002603A2 (fr) * 1993-07-14 1995-01-26 Pharmacia S.P.A. Utilisation des derives de cepheme comme agents anti-metastatiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446037A (en) * 1991-12-05 1995-08-29 Synphar Laboratories, Inc. 2-[(substituted) methylene]cephalosporin sulfones as antiinflammatory, antidegenerative and antithrombin agents

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124081A2 (fr) * 1983-05-02 1984-11-07 Merck & Co. Inc. Céphalosporinesulfones comme agents anti-inflammatoires et anti-dégénératifs, compositions pharmaceutiques les contenant et procédés pour les fabriquer
EP0267723A2 (fr) * 1986-11-12 1988-05-18 Merck & Co. Inc. Sulfones de céphalosporine substituées comme agents anti-inflammatoires et anti-dégénératifs
WO1989010926A1 (fr) * 1988-05-13 1989-11-16 Farmitalia Carlo Erba S.R.L. Derives d'acides 1,1-dioxo-cephem-4-carbothioliques
EP0411929A1 (fr) * 1989-08-01 1991-02-06 Merck & Co. Inc. Procédé pour la préparation de céphèmes 1,1-dioxo-7-substituées
WO1991004977A1 (fr) * 1989-10-06 1991-04-18 Synphar Laboratories, Inc. Nouveaux derives de sulfone de cephalosporine 2-spirocyclopropyle et procedes de preparation de tels derives
GB2266526A (en) * 1992-03-17 1993-11-03 Merck & Co Inc Substituted cephalosporin sulfones useful in the treatment of leukemia
GB2266525A (en) * 1992-03-17 1993-11-03 Merck & Co Inc Substituted cephalosporin sulfone compositions useful in the treatment of leukemia
DE4341332A1 (de) * 1992-12-04 1994-06-09 Erba Carlo Spa 4-Alkyl- und 4-Alkenyl-Delta-3-Cephemsulfone
WO1994028003A1 (fr) * 1993-05-20 1994-12-08 Pharmacia S.P.A. Cefemsulfones tricycliques
WO1995002603A2 (fr) * 1993-07-14 1995-01-26 Pharmacia S.P.A. Utilisation des derives de cepheme comme agents anti-metastatiques

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
ALPEGIANI, M. ET AL: "Synthesis and evaluation of new elastase inhibitors. I. 1,1-Dioxocephem-4-[carboxylic acid] thiol esters", EUR. J. MED. CHEM. (1992), 27(9), 875-90, XP000857084 *
ALPEGIANI, MARCO ET AL: "Studies on cephem sulfones as mechanism-based inactivators of human leukocyte elastase. III. Reactions ensuing from chemical.beta.-lactam cleavage", BIOORG. MED. CHEM. LETT. (1993), 3(11), 2259-64, XP002126771 *
ALPEGIANI, MARCO ET AL: "Unexpected reaction between DCC and cephalosporanic acid sulphones", HETEROCYCLES (1990), 31(1), 139-47, XP002126776 *
APLIN, ROBIN T. ET AL: "An investigation into the mechanism of elastase inhibition by cephalosporins using electrospray ionization mass spectrometry", TETRAHEDRON (1993), 49(47), 10903-12, XP002126773 *
BLACKLOCK, THOMAS J. ET AL: "A versatile synthesis of 1,1-dioxo 7-substituted cephems: preparation of the human leukocyte elastase (HLE) inhibitor 1,1-dioxo-trans-7-methoxycephalosporanic acid tert-butyl ester", J. ORG. CHEM. (1989), 54(16), 3907-13, XP002126781 *
BORGHI, DANIELA ET AL: "Ring conformation and proton NMR spectra of cephem sulfones. Origin and diagnostic value of the H-6, H-2.alpha. long-range coupling", GAZZ. CHIM. ITAL. (1991), 121(5), 273-5, XP002126775 *
DOHERTY, JAMES B. ET AL: "Cephalosporin antibiotics can be modified to inhibit human leukocyte elastase", NATURE (LONDON) (1986), 322(6075), 192-4, XP002126782 *
DOHERTY, JAMES B. ET AL: "Inhibition of human leukocyte elastase. 1. Inhibition by C-7-substituted cephalosporin tert-butyl esters", J. MED. CHEM. (1990), 33(9), 2513-21, XP000857085 *
FINKE, PAUL E. ET AL: "Inhibition of human leukocyte elastase. 2. Inhibition by substituted cephalosporin esters and amides", J. MED. CHEM. (1990), 33(9), 2522-8, XP000857086 *
HAGMANN, WILLIAM K. ET AL: "Inhibition of human leukocyte elastase by C-2 substituted cephalosporin sulfones", EUR. J. MED. CHEM. (1989), 24(6), 599-604, XP000651452 *
M. ALPEGIANI ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, 1994, WASHINGTON US, pages 4003 - 4019, XP002077984 *
P E FINKE ET AL: "Inhibition of Human Leukocyte Elastase. 4. Selection of a Substituted Cephalosporin (L-658,758) as a Topical Aerosol", JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 35, 1992, pages 3731 - 3744, XP002077983, ISSN: 0022-2623 *
RIZZO, VINCENZO ET AL: "Studies on cephem sulfones as mechanism-based inactivators of human leukocyte elastase. IV. Reactions ensuing from enzymic.beta.-lactam cleavage", BIOORG. MED. CHEM. LETT. (1993), 3(11), 2265-70, XP002126772 *
SALYI, SZABOLCS ET AL: "An improved stereospecific preparation of 7.alpha.- alkoxycephalosporins", SYNTH. COMMUN. (1996), 26(3), 445-52, XP002126770 *
See also references of WO9708174A1 *
SHAH, SHRENIK K. ET AL: "Inhibition of human leukocyte elastase. 3. Synthesis and activity of 3'-substituted cephalosporins", J. MED. CHEM. (1990), 33(9), 2529-35, XP000857087 *

Also Published As

Publication number Publication date
EP0859779A1 (fr) 1998-08-26
WO1997008174A1 (fr) 1997-03-06
JPH11511463A (ja) 1999-10-05

Similar Documents

Publication Publication Date Title
PL328527A1 (en) Inhibitors of interleukin-1beta converting enzyme
HUP9902254A3 (en) Inhibitors of interleukin-1beta converting enzyme
PL318220A1 (en) Inhibitors of interleukin-1 converting enzyme
IL117060A0 (en) Multifunctional enzyme
EP0837933A4 (fr) Minizymes et miniribozymes optimises et utilisation de ces derniers
AU1399997A (en) Apoptosis inducers
AU6162896A (en) Human chemokine beta-11 and human chemokine alpha-1
AU6587596A (en) Culture vessel and assembly
AU5383498A (en) Human chemokine beta-13
AU1916795A (en) Human chemokine beta-11 and human chemokine alpha-1
ZA9610798B (en) Inhibitors of interleuken-1beta converting enzyme
EP0851760A4 (fr) Enzyme de conversion d'interleukines et apoptose
AU7250494A (en) Interleukin-1 beta converting enzyme like apoptosis protease-1 and 2
AU2698795A (en) Human chemokine beta-12
ZA964862B (en) Optimized minizymes and miniribozymes and uses thereof
GB9505475D0 (en) Enzyme
GB2293288B (en) Conversion between analogue and digital signals
GB9505479D0 (en) Enzyme
AU1578597A (en) Frictional interface between bodies
IL118404A0 (en) Enzyme degrading rhamnogalacturonane II its preparation and use
AU5188296A (en) Carbopeptoids and carbonucleotoids
GB9623539D0 (en) Enzymes and their use
GB9407484D0 (en) Enzyme
GB9617184D0 (en) Enzyme
AU3617097A (en) Pro-protein converting enzyme

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 20000225

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE ES FR GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000524